Discover
ARTL
Artelo Biosciences, Inc.
0.74
1 x 0.72
1 x 0.75
bid
ask
+
0.04
5.30%
01:37 PM
timesize
| Ytd | -79.71% | |
| 1y | -97.53% |
0.72
day range
0.76
0.70
52 week range
31.65
| Open | 0.72 | Prev Close | 0.71 | Low | 0.72 | High | 0.76 | Mkt Cap | 2.59M |
| Vol | 77.21K | Avg Vol | 1.14M | EPS | -20.24 | P/E | -0.04 | Forward P/E | -1.10 |
| Beta | -0.07 | Short Ratio | 1.65 | Inst. Own | 0.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.11 | 200-d Avg | 3.97 | 1yr Est | 5.00 |
| Income Statement | |||
| Operating Expenses | 2.69M | ||
| Research and Development Expense | 773.00K | ||
| Selling, General and Administrative Expense | 1.92M | ||
| Operating Income | -2.69M | ||
| Interest Expense | 124.00K | ||
| Net Income | -2.96M | ||
| Net Income Common Stock | -2.96M | ||
| Net Income Common Stock (USD) | -2.96M | ||
| Consolidated Income | -2.96M | ||
| Earnings per Basic Share | -4.00 | ||
| Earnings per Basic Share (USD) | -4.00 | ||
| Earnings per Diluted Share | -4.00 | ||
| Earning Before Interest & Taxes (EBIT) | -2.83M | ||
| Earning Before Interest & Taxes (USD) | -2.83M | ||
| Weighted Average Shares | 739.00K | ||
| Weighted Average Shares Diluted | 739.00K | ||
| Balance Sheet | |||
| Cash and Equivalents | 10.27M | ||
| Cash and Equivalents (USD) | 10.27M | ||
| Current Assets | 10.42M | ||
| Property, Plant & Equipment Net | 55.00K | ||
| Total Assets | 12.52M | ||
| Debt Current | 701.00K | ||
| Total Debt | 719.00K | ||
| Current Liabilities | 5.83M | ||
| Debt Non-Current | 18.00K | ||
| Total Liabilities | 5.85M | ||
| Accumulated Retained Earnings (Deficit) | -65.97M | ||
| Accumulated Other Comprehensive Income | -246.00K | ||
| Shareholders Equity | 6.67M | ||
| Shareholders Equity (USD) | 6.67M | ||
| Assets Non-Current | 2.10M | ||
| Total Debt (USD) | 719.00K | ||
| Goodwill and Intangible Assets | 2.04M | ||
| Liabilities Non-Current | 18.00K | ||
| Trade and Non-Trade Payables | 4.51M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 9.00K | ||
| Net Cash Flow from Financing | 10.86M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 9.67M | ||
| Issuance (Purchase) of Equity Shares | 10.27M | ||
| Issuance (Repayment) of Debt Securities | 593.00K | ||
| Net Cash Flow from Operations | -1.19M | ||
| Effect of Exchange Rate Changes on Cash | 4.00K | ||
| Share Based Compensation | 401.00K | ||